TNFRSF8 and cancer: They have been designed to target the CD38, such as the daratumumab (Darzalex, Janssen Biotech, Inc. Horsham, PA), the daratumumab/hyaluronidase (Darzalex Faspro, Janssen Biotech, Inc. Horsham, PA), and the isatuximab (Sarclisa, Sanofi-Aventis, Bridgewater, NJ), or they are CD30-directed Antibody Drug conjugate (ADC), meaning that they consist of a targeted therapy monoclonal antibody and an antineoplastic (chemotherapy) agent that work together to destroy cancer cells, such as the brentuximab vedotin (Adcetris, Seattle Genetics, Inc. Bothell, WA).